Literature DB >> 11358746

Initiation and discontinuation of antiepileptic drugs.

C O'Dell1, S Shinnar.   

Abstract

The issues of when to initiate and discontinue antiepileptic drugs (AEDs) are reviewed using an approach that emphasizes weighing the relative risks and benefits of the therapeutic decisions. The majority of children and adults who present with a first unprovoked seizure will not experience further seizures. Treatment reduces recurrence risk but does not alter long-term prognosis. Treatment should be deferred until a second seizure has occurred. The majority of children and adults who are seizure free for two or more years on medications will remain so when medications are withdrawn. The risk of reoccurrence is somewhat higher in adults. The consequences of recurrence are much more significant in adults. Most children who are seizure free on medications should have at least one attempt at medication withdrawal. In adults, the decisions need to be individualized based on a variety of factors including age, sex, occupation, and the presence or absence of risk factors for reoccurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358746     DOI: 10.1016/s0733-8619(05)70020-7

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  3 in total

1.  Seizures and epilepsy in children.

Authors:  Anita Sharma
Journal:  Indian J Pediatr       Date:  2013-09-19       Impact factor: 1.967

2.  Stopping antiepileptic drugs: when and why?

Authors:  John D Hixson
Journal:  Curr Treat Options Neurol       Date:  2010-06-26       Impact factor: 3.598

3.  International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe.

Authors:  Sofie F M Bhatti; Luisa De Risio; Karen Muñana; Jacques Penderis; Veronika M Stein; Andrea Tipold; Mette Berendt; Robyn G Farquhar; Andrea Fischer; Sam Long; Wolfgang Löscher; Paul J J Mandigers; Kaspar Matiasek; Akos Pakozdy; Edward E Patterson; Simon Platt; Michael Podell; Heidrun Potschka; Clare Rusbridge; Holger A Volk
Journal:  BMC Vet Res       Date:  2015-08-28       Impact factor: 2.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.